Echosens

23/12/2025

✴️ We are proud to be part of LiverScreen, a major EU project dedicated to advancing early detection of chronic liver disease (CLD).

Thanks to FibroScan®, 30 000 subjects from the general population in 9 European countries were screened.

The results are alarming: 30% had steatosis, 5% had fibrosis—placing them on a path toward liver cirrhosis and liver cancer—and 70% had metabolic risk factors such as overweight, obesity, type 2 diabetes, or excessive alcohol consumption.

Now that we better understand the risk factors for developing CLD, the first priority is to empower people by raising awareness of what they can change and improve to protect their liver health—because change truly matters.

➡️ Learn more about the liver health concept in this video from LiverScreen: https://www.liverscreen.eu/

19/12/2025

✨ Echosens wishes you a joyful, festive season!

As we close this year, we want to thank our partners, colleagues, and community for their trust and collaboration. We look forward to achieving great things together in the year ahead!

17/12/2025

Another practice is raising the bar for liver health! 🌟 We’re proud to highlight T.J. Regional Health GI Clinic as part of the .

By integrating FibroScan®, they’re making liver care more accessible in Kentucky – supporting prevention, early detection, and overall metabolic health.

🎉 Thank you to the T.J. Regional Health GI team for their leadership in empowering providers and patients alike with tools for earlier detection and better long-term health. Together, we’re building stronger communities through liver health awareness and action. 👏

15/12/2025

A recent media feature perfectly captures something we care deeply about at Echosens: the connection between company culture, innovation, and impact.

👏 “The Echosens Blueprint: A Top Workplace as a Growth Engine” highlights the story we’re most proud of—how empowering teams and investing in purpose fuels progress in liver health.

The article discusses:
🔹Our recent Top Places to Work accolade
🔹How Guided VCTE™ and the LHM platform are elevating non-invasive liver management
🔹Strategic partnerships with pharmaceutical companies, such as Boehringer Ingelheim and Novo Nordisk
🔹And the FDA’s acceptance of our letter of intent to qualify LSM by VCTE (FibroScan®) as the first non-invasive surrogate endpoint in MASH clinical trials

It’s a great snapshot of the past couple of years, where we’re heading, and why people are the engine behind it all.

Full story 👉 https://briefglance.com/articles/the-echosens-blueprint-a-top-workplace-as-a-growth-engine

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

12/12/2025

Would you like to learn more about Multi-Disciplinary Care but missed our webinar session?

📺Register now to watch the webinar replay on-demand with Dr. Martin Grajower, Dr. Darryn Potosky, and Dr. Radhika Vayani.
They will share their real-world perspectives on how coordinated care across specialties can improve early detection and management of metabolic disease.

In particular, you will be able to:
🔸Learn how collaboration between primary care, endocrinology, and hepatology enhances patient outcomes
🔸Review practical approaches to streamline early metabolic disease detection and its role in MASLD management.

Register here ➡️ https://gateway.on24.com/wcc/eh/1905202/lp/5149148/from-awareness-to-action-how-multi-disciplinary-care-can-drive-earlier-detection-of-metabolic-disease?utm_source=facebook

10/12/2025

📢 FibroScan® in the Spotlight!

We’re honored to see FibroScan® (VCTE) highlighted in editorial of January 2026 issue of The Lancet Gastroenterology & Hepatology : Accelerating MASH trials: from biopsy to biomarkers. This recognition aligns with the FDA’s acceptance of our Letter of Intent, the first step toward qualifying Liver Stiffness Measurement (LSM) by VCTE as a potential surrogate endpoint in MASH trials. A major leap forward for non-invasive liver assessment!

As we move ahead, we’re ready to support Pharma sponsors in optimizing LSM integration and ensuring robust data quality through our proven FibroScan Quality Assurance Program.

The future of liver care is here—let’s build it together! 💙

👉 Read the article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00352-8/fulltext

08/12/2025

Echosens is honored to be recognized by The Boston Globe as one of Massachusetts’ 2025 Top Places to Work, marking our second consecutive year on the list. 🏆

Our team’s shared commitment to advancing liver health continues to shape a workplace grounded in purpose, collaboration, and respect. We extend our sincere appreciation to every member of the team whose insights and dedication make Echosens an exceptional place to work.

👉 Read our press release for full details: https://www.prnewswire.com/news-releases/echosens-named-a-top-place-to-work-in-2025-by-the-boston-globe-302634249.html?tc=eml_cleartime

05/12/2025

🌍 Progress in liver and metabolic health doesn’t happen alone.

At Echosens, we believe solid partnerships drive stronger outcomes. We’re proud to work alongside pharma, biotech, and healthcare providers at every step of the journey to detect disease earlier and improve outcomes for patients everywhere.

Through collaboration, we’re:
🔹Supporting more than 40 pharmaceutical and biotech companies advancing MASH research and treatment.
🔹Helping care teams integrate FibroScan® and its VCTE™ probe and elastography system seamlessly into clinical workflows.
🔹Providing dedicated clinical, service, and market access support.
🔹Powering progress with digital tools like the Liver Health Management (LHM) platform and myFibroScan® app.

Together, we’re transforming how liver and metabolic health are managed—from detection to prevention, and from data to better care. Because progress is strongest when it’s shared. 🤝

FibroScan® is only the beginning of our journey. Let’s move liver and metabolic health forward—together.

03/12/2025

🎉This week we are celebrating Endocrinology Associate’s four-year anniversary with the !
We’re grateful for your partnership in bringing liver health assessments to more patients! Together, we can help drive awareness of MASLD and the importance of early detection and monitoring.

🙏Thank you for being a part of this journey and we look forward to many more milestones to come!

➡️Tag your practice that is part of the . We’d love to hear about your program!

01/12/2025

Metabolic health plays a critical role in mitigating chronic disease progression and improving overall well-being. Obesity is a leading driver of poor metabolic health, fueling conditions like type 2 diabetes, heart disease, cancer, and steatotic liver disease.

These conditions are a major cost driver for employers and a constant challenge for on-site clinics that aim to keep employees healthy and productive. That’s why screening for metabolic dysfunction-associated steatotic liver disease (MASLD) should no longer be seen as optional. The liver is a window to understanding overall metabolic health, and early detection of disease can help mitigate associated cardiometabolic risk factors like heart attack, stroke, diabetes progression, and even cancer.

FibroScan® is the gold standard solution. This non-invasive, point-of-care tool delivers a comprehensive liver assessment in just minutes with immediate results—accelerating decision-making for a quicker path to better health.

Backed by 5,600+ publications and included in nearly 220 international guidelines, FibroScan® enables employers and onsite clinics to take a proactive approach to metabolic health, improving outcomes while controlling costs.

👉 It’s time to screen metabolic health comprehensively—for your workforce, your clinic, and your bottom line.

28/11/2025

Today we want to congratulate our providers at Be Well Primary Care! Last month, they added their 5th location to the in Fort Worth, TX!

We love seeing the growth quickly unfold over time as customers see the value of FibroScan® for their patients. Bringing noninvasive screening to patients at the point-of-care is making liver health management accessible for all.

🤗Thank you, Dr. Vayani and the rest of the Be Well staff, for joining Echosens in the fight against MASLD!

📣Know a practice that is already part of the that deserves a shout out? We’d love to hear about them!

26/11/2025

We’ve long known the “big five” risk factors for atherosclerotic disease—diabetes, hypertension, smoking, low HDL, and high LDL.

Now, evidence shows something just as important: steatotic liver disease is an independent cardiovascular risk factor. Yet many clinicians still view it as secondary to other metabolic conditions, overlooking its direct impact on heart health.

🎥 In this clip, Dr. Martin Grajower explains why that mindset needs to shift.

🔗 For more in-depth insights from Dr. Grajower, read “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/